ZA201800056B - Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders - Google Patents
Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disordersInfo
- Publication number
- ZA201800056B ZA201800056B ZA2018/00056A ZA201800056A ZA201800056B ZA 201800056 B ZA201800056 B ZA 201800056B ZA 2018/00056 A ZA2018/00056 A ZA 2018/00056A ZA 201800056 A ZA201800056 A ZA 201800056A ZA 201800056 B ZA201800056 B ZA 201800056B
- Authority
- ZA
- South Africa
- Prior art keywords
- skin disorders
- methods
- nicotinamide riboside
- compositions
- treatment
- Prior art date
Links
- 208000017520 skin disease Diseases 0.000 title abstract 8
- 239000000203 mixture Substances 0.000 title abstract 6
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 235000020956 nicotinamide riboside Nutrition 0.000 title abstract 3
- 239000011618 nicotinamide riboside Substances 0.000 title abstract 3
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 title abstract 3
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 230000036561 sun exposure Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173733P | 2015-06-10 | 2015-06-10 | |
| PCT/US2016/019653 WO2016200447A1 (en) | 2015-06-10 | 2016-02-25 | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201800056B true ZA201800056B (en) | 2023-10-25 |
Family
ID=57503873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/00056A ZA201800056B (en) | 2015-06-10 | 2018-01-04 | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11426398B2 (enExample) |
| EP (1) | EP3307754B1 (enExample) |
| JP (1) | JP2018517774A (enExample) |
| KR (1) | KR20180021784A (enExample) |
| CN (1) | CN107849083A (enExample) |
| AU (2) | AU2016274126A1 (enExample) |
| CA (1) | CA2989115C (enExample) |
| ES (1) | ES2932801T3 (enExample) |
| MX (2) | MX389207B (enExample) |
| RU (1) | RU2017145692A (enExample) |
| TW (1) | TWI725033B (enExample) |
| WO (1) | WO2016200447A1 (enExample) |
| ZA (1) | ZA201800056B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107849083A (zh) | 2015-06-10 | 2018-03-27 | 益力舒健康公司 | 用于治疗皮肤病症的烟酰胺核苷和紫檀芪组合物和方法 |
| WO2018133139A1 (zh) | 2017-01-21 | 2018-07-26 | 宁波知明生物科技有限公司 | 芍药苷-6'-o-苯磺酸酯在治疗干燥综合征的应用 |
| WO2018170389A1 (en) * | 2017-03-17 | 2018-09-20 | Elysium Health, Inc. | Nicotinamide riboside for use in treating or preventing liver damage |
| US11129843B2 (en) * | 2017-04-24 | 2021-09-28 | Elysium Health, Inc. | Treating and preventing kidney damage |
| ES3004332T3 (en) | 2017-05-17 | 2025-03-12 | Univ De Valencia Estudi General | Treating and preventing amyotrophic lateral sclerosis with nicotinamide riboside and pterostilbene |
| EP3624808A4 (en) * | 2017-05-18 | 2021-03-03 | Elysium Health, Inc. | PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP |
| CA3108015A1 (en) * | 2017-07-28 | 2019-01-31 | Centers For Age Control, Inc. | Compositions and methods for preventing and reversing aspects of aging |
| CN109589309A (zh) * | 2017-09-30 | 2019-04-09 | 浙江嘉华化工有限公司 | 烟酰胺核糖微囊的制备方法 |
| WO2019079686A1 (en) * | 2017-10-19 | 2019-04-25 | Elysium Health, Inc. | PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH TDP-43 |
| WO2019108875A1 (en) * | 2017-12-01 | 2019-06-06 | Elysium Health, Inc. | Methods and compositions for treating glaucoma |
| WO2019108873A1 (en) * | 2017-12-01 | 2019-06-06 | Elysium Health, Inc. | Methods and compositions for treating multiple sclerosis |
| GB201811312D0 (en) * | 2018-07-10 | 2018-08-29 | Nuchido Ltd | Compositions |
| CN112955139B (zh) | 2018-09-25 | 2025-04-18 | 庞塞迪利昂健康特定活动公司 | 用于制备α-酮戊二酸钙的方法 |
| CN111569084B (zh) * | 2019-02-19 | 2021-07-13 | 中国科学院上海药物研究所 | 基于柳胺酚和紫檀芪的成环偶联分子dcz0801类化合物、其制备方法及用途 |
| JP7580380B2 (ja) * | 2019-02-26 | 2024-11-11 | ウニベルシタット デ バレンシア―エストゥディ ジェネラル | 運動ニューロン疾患を処置するための方法及び組成物 |
| WO2020190703A1 (en) * | 2019-03-21 | 2020-09-24 | Elysium Health, Inc. | Methods for wound treatment |
| CN113712193A (zh) * | 2020-05-25 | 2021-11-30 | 南京帝昌医药科技有限公司 | 修复皮肤系统的组合物制备方法及其用途 |
| CN113768946A (zh) * | 2020-05-25 | 2021-12-10 | 南京帝昌医药科技有限公司 | 一种治疗糖尿病皮肤并发症的软膏及其制备方法 |
| US20230270770A1 (en) * | 2020-07-30 | 2023-08-31 | Moises HERNANDEZ-VAZQUEZ | Nutritional supplements for repairing muscle and defending against deterioration from human aging |
| EP4380577A1 (en) * | 2021-08-02 | 2024-06-12 | Nuvamid SA | Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO2007061798A2 (en) * | 2005-11-18 | 2007-05-31 | Cornell Research Foundation, Inc. | Nicotinoyl riboside compositions and methods of use |
| EP2322159A1 (en) | 2009-10-30 | 2011-05-18 | Green Molecular, S.L. | Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic |
| WO2012129499A1 (en) | 2011-03-23 | 2012-09-27 | The Regents Of The University Of California | Treatment of inflammatory and infectious skin disorders |
| US8841350B2 (en) | 2011-05-11 | 2014-09-23 | ChromaDex Inc. | Method for inducing UDP-glucuronosyltransferase activity using pterostilbene |
| US20130296440A1 (en) | 2012-05-01 | 2013-11-07 | ChromaDex Inc. | Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation |
| JP6509844B2 (ja) * | 2013-10-30 | 2019-05-08 | クロマデックス, インコーポレイテッドChromaDex, Inc. | 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物 |
| RU2016149767A (ru) * | 2014-06-06 | 2018-07-16 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Аналоги никотинамидрибозида и фармацевтические композиции и их применение |
| NZ735411A (en) * | 2015-03-16 | 2021-07-30 | Chromadex Inc | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof |
| WO2016149277A1 (en) * | 2015-03-17 | 2016-09-22 | Specialty Nutrition Group, Inc. | Nutritional compositions to enhance mitochondrial energy production |
| CN107849083A (zh) | 2015-06-10 | 2018-03-27 | 益力舒健康公司 | 用于治疗皮肤病症的烟酰胺核苷和紫檀芪组合物和方法 |
-
2016
- 2016-02-25 CN CN201680046668.7A patent/CN107849083A/zh active Pending
- 2016-02-25 AU AU2016274126A patent/AU2016274126A1/en not_active Abandoned
- 2016-02-25 WO PCT/US2016/019653 patent/WO2016200447A1/en not_active Ceased
- 2016-02-25 JP JP2018517123A patent/JP2018517774A/ja active Pending
- 2016-02-25 KR KR1020187000353A patent/KR20180021784A/ko not_active Ceased
- 2016-02-25 ES ES16807940T patent/ES2932801T3/es active Active
- 2016-02-25 CA CA2989115A patent/CA2989115C/en active Active
- 2016-02-25 EP EP16807940.8A patent/EP3307754B1/en active Active
- 2016-02-25 US US15/735,066 patent/US11426398B2/en active Active
- 2016-02-25 RU RU2017145692A patent/RU2017145692A/ru unknown
- 2016-02-25 MX MX2017016024A patent/MX389207B/es unknown
- 2016-06-13 TW TW105118370A patent/TWI725033B/zh active
-
2017
- 2017-12-08 MX MX2021012600A patent/MX2021012600A/es unknown
-
2018
- 2018-01-04 ZA ZA2018/00056A patent/ZA201800056B/en unknown
-
2020
- 2020-12-08 AU AU2020286208A patent/AU2020286208B2/en active Active
-
2022
- 2022-07-25 US US17/872,575 patent/US12109206B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX389207B (es) | 2025-03-20 |
| AU2020286208B2 (en) | 2022-11-10 |
| AU2016274126A1 (en) | 2018-01-18 |
| CA2989115A1 (en) | 2016-12-15 |
| EP3307754B1 (en) | 2022-09-14 |
| RU2017145692A (ru) | 2019-07-10 |
| AU2020286208A1 (en) | 2021-01-07 |
| ES2932801T3 (es) | 2023-01-26 |
| JP2018517774A (ja) | 2018-07-05 |
| US11426398B2 (en) | 2022-08-30 |
| CN107849083A (zh) | 2018-03-27 |
| US20220362233A1 (en) | 2022-11-17 |
| EP3307754A1 (en) | 2018-04-18 |
| CA2989115C (en) | 2024-01-02 |
| KR20180021784A (ko) | 2018-03-05 |
| RU2017145692A3 (enExample) | 2019-07-31 |
| MX2021012600A (es) | 2021-11-12 |
| EP3307754A4 (en) | 2019-03-27 |
| TWI725033B (zh) | 2021-04-21 |
| WO2016200447A1 (en) | 2016-12-15 |
| MX2017016024A (es) | 2018-08-15 |
| US12109206B2 (en) | 2024-10-08 |
| TW201713322A (zh) | 2017-04-16 |
| US20180353497A1 (en) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021012600A (es) | Composiciones de nicotinamida ribosido y pteroestilbeno y metodos para el tratamiento de trastornos de la piel. | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| MX2018011114A (es) | Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías. | |
| ZA202101797B (en) | Hair treatment compositions, methods, and kits for treating hair | |
| MX2020001774A (es) | Composiciones y métodos para tratar enfermedad colestásica. | |
| ZA201901536B (en) | Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders | |
| IL276808A (en) | Preparations and methods for the treatment of cancer | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| NZ631701A (en) | Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MY187540A (en) | Compounds active towards bromodomains | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| SG10201808835QA (en) | Anti-siglec-8 antibodies and methods of use thereof | |
| WO2017079570A3 (en) | Splise-switching oligonucleotides and methods of use | |
| JOP20200022A1 (ar) | مركبات حلقية لولبية وطرق تصنيعها واستخدامها | |
| MX2019009753A (es) | Composicion y metodos para prevenir lesion por radiacion y promover la regeneracion de tejidos. | |
| MX2017002489A (es) | Agentes terapeuticos humanos. | |
| MY195081A (en) | Pladienolide Pyridine Compounds and Methods of use | |
| MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
| SG10201805890QA (en) | Compositions and methods for treatment of abnormal cell growth | |
| TW201713323A (en) | Therapeutic compositions and methods of use thereof | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| MX2017013047A (es) | Tratamiento de dolor. | |
| PH12016501838A1 (en) | Compounds and their methods of use |